133 related articles for article (PubMed ID: 25340478)
1. Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB.
Sniderman AD; Lamarche B; Contois JH; de Graaf J
Curr Opin Lipidol; 2014 Dec; 25(6):461-7. PubMed ID: 25340478
[TBL] [Abstract][Full Text] [Related]
2. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study.
Sniderman AD; Islam S; Yusuf S; McQueen MJ
Atherosclerosis; 2012 Dec; 225(2):444-9. PubMed ID: 23068583
[TBL] [Abstract][Full Text] [Related]
3. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?
Sniderman A; McQueen M; Contois J; Williams K; Furberg CD
J Clin Lipidol; 2010; 4(3):152-5. PubMed ID: 21122647
[TBL] [Abstract][Full Text] [Related]
4. Is the superiority of apoB over non-HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables?
Sniderman AD; Islam S; Yusuf S; McQueen MJ
J Clin Lipidol; 2013; 7(6):626-31. PubMed ID: 24314360
[TBL] [Abstract][Full Text] [Related]
5. Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study.
Idris I; Tate H; Ahmad A; McCormack T
J Clin Lipidol; 2011; 5(4):316-23. PubMed ID: 21784378
[TBL] [Abstract][Full Text] [Related]
6. Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population.
Martinez-Hervas S; Real JT; Priego MA; Carratalá A; Sniderman AD; Carmena R; Ascaso JF
Int J Clin Pract; 2013 Jan; 67(1):81-8. PubMed ID: 23241052
[TBL] [Abstract][Full Text] [Related]
7. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
[TBL] [Abstract][Full Text] [Related]
8. Update on the detection and treatment of atherogenic low-density lipoproteins.
Sniderman A; Kwiterovich PO
Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):140-7. PubMed ID: 23422241
[TBL] [Abstract][Full Text] [Related]
9. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
Olson EJ; Pearce GL; Jones NP; Sprecher DL
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748
[TBL] [Abstract][Full Text] [Related]
10. Discordance between apolipoprotein B or non-HDL-cholesterol and LDL-cholesterol in middle-aged and elderly Chinese patients predicts arterial stiffness.
Qu G; Zhang Z; Zhu H
Lipids Health Dis; 2021 Jul; 20(1):80. PubMed ID: 34325713
[TBL] [Abstract][Full Text] [Related]
11. [What is a good marker for serum cholesterol to identify high-risk patients at general health checks?].
Fujioka Y
Rinsho Byori; 2012 Apr; 60(4):328-35. PubMed ID: 22686042
[TBL] [Abstract][Full Text] [Related]
12. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk.
Sniderman AD; St-Pierre AC; Cantin B; Dagenais GR; Després JP; Lamarche B
Am J Cardiol; 2003 May; 91(10):1173-7. PubMed ID: 12745098
[TBL] [Abstract][Full Text] [Related]
13. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
14. An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB.
Sniderman AD; Toth PP; Thanassoulis G; Furberg CD
J Clin Lipidol; 2016; 10(5):1248-58. PubMed ID: 27678443
[TBL] [Abstract][Full Text] [Related]
15. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.
Sniderman AD; Jungner I; Holme I; Aastveit A; Walldius G
J Intern Med; 2006 May; 259(5):455-61. PubMed ID: 16629851
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein B (apoB) more closely related to subclinical atherosclerosis than non-HDL cholesterol and LDL cholesterol.
Walldius G
J Intern Med; 2010 Dec; 268(6):549-51. PubMed ID: 21091807
[No Abstract] [Full Text] [Related]
17. ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management.
de Nijs T; Sniderman A; de Graaf J
Crit Rev Clin Lab Sci; 2013 Nov; 50(6):163-71. PubMed ID: 24295059
[TBL] [Abstract][Full Text] [Related]
18. A potential role of apolipoprotein B in the risk stratification of diabetic patients with dyslipidaemia.
Al-Bahrani AI; Bakhiet CS; Bayoumi RA; Al-Yahyaee SA
Diabetes Res Clin Pract; 2005 Jul; 69(1):44-51. PubMed ID: 15904989
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
[TBL] [Abstract][Full Text] [Related]
20. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
